Tandem Diabetes Care (TNDM) Gross Profit (2013 - 2026)

Tandem Diabetes Care's Gross Profit history runs 14 years deep, the most recent figure standing at $136.8 million for Q1 2026.

• Quarterly Gross Profit rose 15.52% year-over-year to $136.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $564.4 million (up 9.95% YoY) and the FY2025 annual result came in at $546.0 million, up 11.53% from the prior year.
• Gross Profit was $136.8 million for Q1 2026 at Tandem Diabetes Care, down from $167.5 million in the prior quarter.
• Across five years, Gross Profit topped out at $167.5 million in Q4 2025 and bottomed at $82.9 million in Q1 2023.
• A 5-year average of $114.9 million and a median of $112.8 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit dropped 19.24% — and 2024, when it soared 68.77%.
• Tandem Diabetes Care's Gross Profit stood at $115.5 million in 2022, then fell by 19.24% to $93.3 million in 2023, then surged by 68.77% to $157.5 million in 2024, then rose by 6.35% to $167.5 million in 2025, then dropped by 18.32% to $136.8 million in 2026.
• Business Quant data shows TNDM's Gross Profit at $136.8 million in Q1 2026, $167.5 million in Q4 2025, and $134.3 million in Q3 2025.